Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report)’s stock price passed below its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $117.58 and traded as low as $114.40. Kymera Therapeutics shares last traded at $115.10, with a volume of 1,278,323 shares trading hands.
Analysts Set New Price Targets
A number of brokerages recently issued reports on KYMR. Bank of America increased their price objective on Kymera Therapeutics from $123.00 to $144.00 and gave the stock a “buy” rating in a research report on Monday, September 14th. Raymond James Financial reaffirmed an “outperform” rating on shares of Kymera Therapeutics in a research report on Thursday, October 29th. Royal Bank Of Canada increased their price objective on shares of Kymera Therapeutics from $112.00 to $116.00 and gave the company a “sector perform” rating in a research report on Friday, October 30th. Wolfe Research raised Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $180.00 target price on the stock in a report on Thursday, September 10th. Finally, Wall Street Zen lowered Kymera Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, October 31st. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $139.16.
Read Our Latest Research Report on Kymera Therapeutics
Kymera Therapeutics Trading Down 3.6%
The company has a market capitalization of $9.83 billion, a PE ratio of -31.80 and a beta of 2.04. The stock’s 50-day moving average is $117.58 and its two-hundred day moving average is $100.51.
Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($1.26) by ($0.06). The company had revenue of $1.35 million during the quarter, compared to analysts’ expectations of $3.28 million. Kymera Therapeutics had a negative return on equity of 22.39% and a negative net margin of 285.33%. The company’s quarterly revenue was up .0% on a year-over-year basis. During the same period in the prior year, the business earned ($0.94) EPS. On average, equities research analysts forecast that Kymera Therapeutics, Inc. will post -3.88 EPS for the current fiscal year.
Insider Buying and Selling at Kymera Therapeutics
In other Kymera Therapeutics news, insider Brian Adams sold 6,371 shares of Kymera Therapeutics stock in a transaction on Friday, September 4th. The shares were sold at an average price of $116.83, for a total value of $744,323.93. Following the transaction, the insider directly owned 50,254 shares of the company’s stock, valued at approximately $5,871,174.82. The trade was a 11.25% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Nello Mainolfi sold 30,000 shares of the company’s stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $113.80, for a total transaction of $3,414,000.00. Following the transaction, the chief executive officer owned 666,568 shares in the company, valued at approximately $75,855,438.40. This trade represents a 4.31% decrease in their position. The SEC filing for this sale provides additional information. 15.98% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Knights of Columbus Asset Advisors LLC raised its stake in shares of Kymera Therapeutics by 0.5% during the 3rd quarter. Knights of Columbus Asset Advisors LLC now owns 18,396 shares of the company’s stock worth $2,056,000 after buying an additional 83 shares during the period. GAMMA Investing LLC boosted its holdings in Kymera Therapeutics by 27.5% in the 2nd quarter. GAMMA Investing LLC now owns 454 shares of the company’s stock valued at $52,000 after purchasing an additional 98 shares during the last quarter. Abel Hall LLC grew its holdings in shares of Kymera Therapeutics by 4.0% during the 3rd quarter. Abel Hall LLC now owns 4,870 shares of the company’s stock worth $544,000 after purchasing an additional 189 shares during the period. Proficio Capital Partners LLC increased its holdings in Kymera Therapeutics by 1.8% in the 2nd quarter. Proficio Capital Partners LLC now owns 11,045 shares of the company’s stock valued at $1,267,000 after purchasing an additional 200 shares during the last quarter. Finally, Glenmede Trust Co. NA increased its stake in Kymera Therapeutics by 3.6% during the first quarter. Glenmede Trust Co. NA now owns 6,779 shares of the company’s stock worth $565,000 after purchasing an additional 235 shares during the period.
About Kymera Therapeutics
Kymera Therapeutics, Inc. is a clinical-stage biotechnology company developing medicines that selectively remove disease-causing proteins from cells. Its approach, known as targeted protein degradation, uses the body’s natural protein-disposal system and is designed to address targets that may be difficult to reach with conventional drugs. The company’s research and development programs include small-molecule protein degraders for conditions involving immune and inflammatory pathways, as well as cancer.
Further Reading
- Five stocks we like better than Kymera Therapeutics
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
